Markets:

Overview

News

Currencies

International

Treasuries

Vera Therapeutics, Inc. - Class A Common Stock (NQ:VERA)

33.72 -1.46 (-4.16%)

Streaming Delayed Price Updated: 11:56 AM EDT, Jul 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Vera Therapeutics, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch ↗

July 11, 2026

Vera Therapeutics (NASDAQ:VERA) said the U.S. Food and Drug Administration granted accelerated approval to TRUTAKNA, or atacicept-vymj, for adults with primary IgA nephropathy at risk for disease...

Via MarketBeat

3 Biotech Firms With Major Potential Catalysts in the Coming Months ↗

June 21, 2026

The pharmaceutical industry is known for big risks and big rewards among investors; those willing to take on the risk may want to watch these firms.

Via MarketBeat

Topics Intellectual Property

Investment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC Filing ↗

May 26, 2026

This biotech focuses on biologic therapies for immunological diseases, with lead candidates in nephrology and infectious disease.

Via The Motley Fool

Topics Regulatory Compliance

Biogen's $5.6 Billion Acquisition of Apellis: A Strategic Pivot into Rare Kidney Diseases

March 31, 2026

In a move that signals a decisive shift away from its traditional focus on neuroscience, Biogen (NASDAQ: BIIB) announced today, March 31, 2026, that it has entered into a definitive agreement to...

Via MarketMinute

High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding ↗

March 21, 2026

This biotechnology firm develops precision therapies for rare, genetically defined diseases, with a focus on targeted cancer treatments.

Via The Motley Fool

Topics Regulatory Compliance

This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know ↗

March 21, 2026

This clinical-stage biotech develops antibody therapies for thyroid eye disease, advancing multiple candidates through its R&D pipeline.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know ↗

March 21, 2026

This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in oncology treatment.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish ↗

March 21, 2026

This clinical-stage biotech focuses on targeted cancer therapies and strategic partnerships in oncology and rare disease treatment.

Via The Motley Fool

This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year ↗

March 20, 2026

This clinical-stage biotech develops therapies for serious immunological diseases, with a focus on late-stage biologic candidates.

Via The Motley Fool

This Biotech Stock Surged 75% Last Quarter and Pulled a New $9 Million Investment ↗

March 16, 2026

Vera Therapeutics develops clinical-stage therapies for serious immunological diseases, with a lead candidate targeting kidney disorders.

Via The Motley Fool

Topics Regulatory Compliance

This Life Sciences Supplier Has Plunged 50% in a Year, but One Fund Bought Up $28 Million More in Stock ↗

March 16, 2026

Avantor delivers laboratory materials and specialized services to biopharma, healthcare, and advanced technology clients worldwide.

Via The Motley Fool

Topics Regulatory Compliance Supply Chain

This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision ↗

March 13, 2026

Vera Therapeutics develops biologic therapies for serious immunological diseases, with a pipeline targeting high-burden conditions.

Via The Motley Fool

Topics Regulatory Compliance

Vertex Pharmaceuticals Surges 8.3% as Renal Breakthrough Sparks Market Rally

March 11, 2026

In a significant milestone for precision medicine, Vertex Pharmaceuticals (NASDAQ:VRTX) emerged as the top performer in the S&P 500 on March 11, 2026, with its shares climbing 8.3%. The rally followed...

Via MarketMinute

Topics Stocks

Vertex Pharmaceuticals Surges as Breakthrough Kidney Data Sets New Gold Standard for IgA Nephropathy

March 10, 2026

Shares of Vertex Pharmaceuticals (Nasdaq: VRTX) climbed more than 8% today, reaching a record high as the biotechnology giant unveiled spectacular interim results from its pivotal Phase 3 RAINIER...

Via MarketMinute

Why Vera Therapeutics Stock Zoomed Higher Today ↗

January 07, 2026

The company has a fine chance of commercializing its leading investigational drug in the near future.

Via The Motley Fool

Why Vera Therapeutics Stock Rocked the Market on Tuesday ↗

December 02, 2025

A competitor recently earned FDA approval, but this drug is reportedly going to be pricey.

Via The Motley Fool

Why Vera Therapeutics Stock Crushed it Today ↗

November 26, 2025

If all goes well, the company will have a drug on the market that could bring in billions of dollars in revenue.

Via The Motley Fool

Get insights into the top gainers and losers of Tuesday's after-hours session. ↗

November 25, 2025

After the closing bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

Via Chartmill

10 Health Care Stocks Whale Activity In Today's Session ↗

November 05, 2025

Via Benzinga

VERA THERAPEUTICS INC (NASDAQ:VERA) Reports Q3 2025 Earnings, Misses EPS Estimates Amid Key Clinical Progress ↗

November 05, 2025

Vera Therapeutics posts Q3 2025 financial results with a widened loss, but key clinical progress for atacicept in IgAN and an upcoming BLA submission drive investor focus.

Via Chartmill

Topics Earnings

Capricorn Fund Loads Up on Phreesia (PHR) With a 484,000 Share Purchase ↗

October 27, 2025

Capricorn Fund Loads Up on Phreesia (PHR) With a 484,000 Share Purchase

Via The Motley Fool

Capricorn Buys New Stake in Ionis Pharmaceuticals (IONS) With 163,000 Shares ↗

October 20, 2025

Via The Motley Fool

Vera Therapeutics' Lead Kidney Drug Poised For 2026 Launch In Multi-Billion-Dollar Market ↗

October 16, 2025

Bank of America initiates coverage on Vera Therapeutics, citing strong potential for atacicept, its kidney treatment.

Via Benzinga

This Celestica Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

October 16, 2025

Via Benzinga

6 Stocks Goldman Sachs Says Are Poised For Potential Acquisition In Next 12 Months — Including A Huge 200% Winner ↗

September 30, 2025

Goldman Sachs has highlighted six stocks that have a high probability of being acquisition targets in the next year.

Via Benzinga

Vera (VERA) Q2 Net Loss Widens 127% ↗

August 06, 2025

Via The Motley Fool

This AvalonBay Communities Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday ↗

August 04, 2025

Via Benzinga

Get insights into the top gainers and losers of Friday's pre-market session. ↗

July 18, 2025

The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Via Chartmill

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

July 18, 2025

Via Benzinga

Analysts Can't Get Enough of These Little-Known Biopharma Stocks

June 12, 2025

Three relatively unknown biopharma firms receive near-unanimous approval from analysts for their promising drug candidates in development.

Via MarketBeat

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.